Alberta’s judge lifts injunction, empowering the province to shield children under 18 from irreversible gender-affirming surgeries and treatments— a bold stand against hasty medicalization that resonates with parents demanding caution.
Story Highlights
- December 19, 2025: Court lifts temporary block on Bill 26, enforcing bans on puberty blockers and hormones for under-16s, surgeries for under-18s.
- United Conservative Party government invokes notwithstanding clause to override Charter challenges, prioritizing minor protection.
- Influenced by U.K. Cass Review citing weak evidence and risks like infertility, aligning with European shifts to therapy-first approaches.
- Advocates Egale Canada and Skipping Stone plan appeals, claiming harm from denied care, while government hails protection of youth.
- Precedent for parental rights and evidence-based policy amid rising detransition concerns.
Timeline of Bill 26 Enforcement
Alberta passed Bill 26 in late 2024, prohibiting puberty blockers and hormone therapy for children under 16 and gender-affirming surgeries for those under 18. Legal challenges from Egale Canada, Skipping Stone, and five youth families cited Charter violations in December 2024. Justice Allison Kuntz granted a temporary injunction on June 27, 2025, halting enforcement due to potential irreparable harm to gender-diverse youth. The government then invoked the notwithstanding clause.
Noteworthy Clause Overrides Judicial Block
On December 19, 2025, the judge lifted the injunction, allowing Bill 26 to take effect. This followed the province’s use of Section 33 of the Canadian Charter, shielding the law from rights-based challenges. Premier Danielle Smith’s United Conservative Party framed the policy as essential to prevent minors from irreversible decisions, echoing global reviews like the U.K.’s Cass Review that questioned puberty blockers’ evidence and highlighted risks including bone density loss and infertility.
Stakeholders and Expert Divide
Pro-restriction experts, including Dr. Hilary Cass, advocate a precautionary approach given high desistance rates—80-90% for pre-pubertal gender dysphoria—and insufficient long-term data. Groups like SEGM support Alberta’s stance. Conversely, WPATH and advocates argue treatments reduce suicide risks, with Justice Kuntz initially noting prejudice reinforcement. Alberta NDP criticizes the ban, while medical bodies comply amid divided evidence from Finland and Sweden favoring therapy over drugs.
Power shifted decisively to the executive via the notwithstanding clause, limiting advocates’ litigation despite planned appeals on criminal grounds. Families gain affirmed parental consent requirements for 16-17-year-olds.
Broader Impacts and Precedents
Short-term, clinics pivot to counseling, denying pharmacological interventions to under-16s and disrupting access claims by trans youth. Long-term, the ruling sets a Canadian precedent for provincial health overrides, potentially curbing transitions amid European detransition trends. UCP bolsters conservative support in Alberta, contrasting progressive provinces, while mirroring Saskatchewan’s policy and U.S. Supreme Court upholding of Tennessee’s ban in 2025. Economic savings may offset litigation costs in millions.
Socially, it polarizes: trans communities cite stigma and distress, yet reinforces traditional protections for minors, addressing frustrations with elite-driven policies over parental and evidentiary safeguards.
Sources:
Calgary CityNews (Jun 27, 2025)
